HMS PLUS INSTRUMENT 30514

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional,l report with the FDA on 2019-03-22 for HMS PLUS INSTRUMENT 30514 manufactured by Perfusion Systems.

Event Text Entries

[139560365] With the information available at this time, medtronic can identify a relationship between the hms plus and the adverse patient outcomes described in the literature. The hms plus was not adequately providing correct information in relation to the infants. As a result, additional heparin was administered which could have potential to the worse outcomes. Date of publish used for incident date. Hms plus model 30514 entered as specific model and serial number were not provided. No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether this event has been previously reported. Citation: gruenwald et al. American college of cardiology (2010) 56, 1794-1802 doi:10. 1016/j. Jacc. 2010. 06. 046 mean patient age of study population used for patient age. Majority gender of study population used for patient gender. If information is provided in the future, a supplemental report will be issued.
Patient Sequence No: 1, Text Type: N, H10


[139560366] Medtronic received information via literature regarding a trial of individualized heparin and protamine management in infants. All data were collected from a single centre between august 2006 and february 2009. The study population included 90 infants younger than 1 year of age (51 male/ 39 female] who underwent cardiac surgery with cardiopulmonary bypass. During the trial, the medtronic hms plus instrument was used for heparin and protamine management for patients randomised to the treatment group (serial numbers not provided). 33 patients were in the hms i group (original protocol using manufacturer's guidelines) with 16 (48%) randomised to treatment arm. 57 patients were in the hms ii group (modified protocol with increase in protamine dose) with 19 (49%) randomised to treatment arm. In the hms i treatment group, the hms plus instrument was found to underestimate actual laboratory plasma anti-xa levels in infants. This caused an overestimated required dose of heparin. The result was significantly poorer clinical outcomes including greater chest tube volume loss, transfusion requirement, intravascular thrombosis along with greater ventilation time, and longer cccu and hospital stay.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number2184009-2019-00008
MDR Report Key8443381
Report SourceFOREIGN,HEALTH PROFESSIONAL,L
Date Received2019-03-22
Date of Report2019-03-22
Date of Event2010-11-23
Date Mfgr Received2019-02-24
Date Added to Maude2019-03-22
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationPHYSICIAN ASSISTANT
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactPAULA BIXBY
Manufacturer Street8200 CORAL SEA STREET NE
Manufacturer CityMOUNDS VIEW MN 55112
Manufacturer CountryUS
Manufacturer Postal55112
Manufacturer Phone7635055378
Manufacturer G1PERFUSION SYSTEMS
Manufacturer Street7611 NORTHLAND DR
Manufacturer CityBROOKLYN PARK MN 55428
Manufacturer CountryUS
Manufacturer Postal Code55428
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameHMS PLUS INSTRUMENT
Generic NameANALYZER, HEPARIN, AUTOMATED
Product CodeJOX
Date Received2019-03-22
Model Number30514
Catalog Number30514
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrN
Device Sequence No1
Device Event Key0
ManufacturerPERFUSION SYSTEMS
Manufacturer Address7611 NORTHLAND DR BROOKLYN PARK MN 55428 US 55428


Patients

Patient NumberTreatmentOutcomeDate
101. Hospitalization 2019-03-22

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.